NCT05166694 Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
| NCT ID | NCT05166694 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2022-11-30 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,300 participants in total. It began in 2022-11-30 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Doctors leading this study will look for variations (differences) in your genes that may suggest that you are at greater risk of having side effects or a greater chance of benefiting from certain medications. Individuals in this study will participate for roughly 9 months.
Eligibility Criteria
Inclusion Criteria: 1. Adult participants cared for by a participating provider at University of Chicago Medical Center. 2. Participants must be at least 18 years of age. 3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information. Exclusion Criteria for Participants 1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation. 2. Participation in another pharmacogenomic study. 3. Participants who have previously received genotyping from another source. 4. Inability to understand and give informed consent to participate. Inclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.
Contact & Investigator
Mark Ratain, MD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT05166694 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05166694 currently recruiting?
Yes, NCT05166694 is actively recruiting participants. Contact the research team at andrehall@bsd.uchicago.edu for enrollment information.
Where is the NCT05166694 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT05166694 clinical trial?
NCT05166694 is sponsored by University of Chicago. The principal investigator is Mark Ratain, MD at University of Chicago. The trial plans to enroll 1,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.